Season 3 of Surfing The NASH Tsunami

S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

S3-E57.5 – From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

In this episode From the Vault, Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his 2021 Paris NASH talk. This conversation revolves around the implications of Lars’s comment that we should track and analyze functioning hepatocyte cells as an excellent marker for liver function.

S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts

S3-E57.4 – Discussing Critical Success Factors for Placebo Cohorts

In discussing the Liver Forum, Executive Director Veronica Miller joins guest Manal Abdelmalek, co-host Jörn Schattenberg and Roger Green to investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. In this final conversation, Veronica, Manal and Jörn each provide their unique perspectives on critical success factors for placebo cohorts.

S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

S3-E57 – The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

In this episode discussing the Liver Forum, Jörn Schattenberg, Manal Abdelmalek, Veronica Miller and Roger Green investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. Jörn, Manal and Veronica each provide their unique introductions to the steering committee and elaborate on the Forum’s efforts toward moving the field forward.

S3-E56.4 - Integrated Solutions for Improved Patient Support

S3-E56.4 – Integrated Solutions for Improved Patient Support

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to discuss integrated solutions to provide more information and better support to patients.

S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

S3-E56.2 – Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. This conversation continues in the theme of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications. Shira describes her own approach, termed weight-inclusive, which focuses on holistic coaching measures which extend to all facets of a happy and healthy lifestyle.

S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

S3-E56.1 – Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are panelists Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. This conversation introduces the topic of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications.

S3-E56 - Focus on the Intersection of Nutrition and NASH

S3-E56 – Focus on the Intersection of Nutrition and NASH

Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green in this rich, applicable and fascinating discussion.

S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations

S3-E55.5 – Pediatric and Lean NASH: Learning from Diverse Populations

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This final conversation discusses the diversity of populations with NASH before closing with the group’s predictions into a new year in the field of Fatty Liver disease.

S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs

S3-E55.4 – Emerging Roles for ELF Test and Advances in Use of PPARs

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation explores emerging roles for the ELF test and advances in the use of PPARs.

S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings

S3-E55.3 – NIT Efficacy in Primary Care and Diabetes Clinic Settings

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation focuses around the efficacy of NITs for identifying fatty liver disease and progression in primary care and diabetes clinic settings.

S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

S3-E55.2 – Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation addresses several topics surrounding the importance of educating physicians on NAFLD prevalence in different systems around the globe, and key points around standardizing AST.

S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

S3-E55 – 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.

S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva

S3-E54.4 – An Interview with Michael Cooreman, CMO of Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. In an exclusive interview, Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk in depth about the company and key elements of its clinical development strategy for its pan-PPAR, lanifibranor.

S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results

S3-E54.3 – Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study’s Phase 3 Results

Surfing the NASH Tsunami hosted two recording sessions throughout the Liver Meeting to discuss key takeaways. This conversation is a composite featuring impressions from both sessions. In the first session, panelists review the emerging role of mitochondrial uncouplers in the field of NASH. The following session offers insight from a reanalysis of results from Intercept’s Phase 3 REGENERATE Study of Obeticholic Acid.

S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis

S3-E54.2 – Presentation on Efruxifermin in NASH with Fibrosis

On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

S3-E54.1 - Utilizing Best Practices in Diagnostics

S3-E54.1 – Utilizing Best Practices in Diagnostics

The 73rd Annual AASLD Liver Meeting proved to be a lively and momentous event held in Washington DC. On the final morning, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe and Jeff McIntyre joined Roger Green to discuss key takeaways and impressions. In this conversation, the panelists focus on utilizing best practices in diagnostics.

S3-E53.1 - The Gut Microbiome and Complexities of NAFLD

S3-E53.1 – The Gut Microbiome and Complexities of NAFLD

Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Liver Meeting on site in Washington DC. In this conversation, the group dives into the gut microbiome while discussing the complex nature of NAFLD.

S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2

S3-E54 – AASLD 2022 Liver Meeting Live Coverage: Part 2

Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discuss key takeaways on the final morning of the 73rd Annual AASLD Liver Meeting. The group embarks on a far reaching conversation to cover at length topics including tests, drugs and nomenclature amongst many more impressions. Following the review, Roger and Stephen interview Michael Cooreman from Inventiva to discuss the focus of the clinical-stage biopharmaceutical company and its relevance to the field of Fatty Liver.

S3-E52.5 - 2022 AASLD Preview: Final Thoughts

S3-E52.5 – 2022 AASLD Preview: Final Thoughts

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in finalizing a second preview of key presentations and posters of interest.

S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools

S3-E52.4 – Exploring the NAFLD-Metabolic Link Through Screening Tools

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. This conversation explores abstracts on the NAFLD-Metabolic link and continues discussion around optimal screening tools.

S3-E52.3 - Remote Wellness Tools and Disease Management

S3-E52.3 – Remote Wellness Tools and Disease Management

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this conversation, the panelists explore the potential of remote wellness tools.

S3-E52.2 - Efficacy of NITs and Predictive Outcomes

S3-E52.2 – Efficacy of NITs and Predictive Outcomes

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Ian shifts discussion toward the efficacy of various NITs and their predictive outcomes.

S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening

S3-E52.1 – FIB-4 and the Way Forward in Primary Care Screening

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Mazen leads discussion on the way forward in diagnosing fibrotic NASH in patients with Type 2 Diabetes.

S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting

S3-E52 – Part 2: A Preview of the 2022 AASLD Liver Meeting

In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

S3-E51.5 - From the Vault: AASLD 2021 Wrap-up

S3-E51.5 – From the Vault: AASLD 2021 Wrap-Up

The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th, 2022 in Washington DC. In this episode From the Vault, Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to promptly recap a just-concluded 2021 AASLD Annual Liver Meeting. Discussion centers around the many areas of advance and novelty in the program, with particular attention to non-invasive testing, genomics and the increased visibility of patients and their needs.

S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

S3-E51.4 – Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation discusses the NAFLD-Cancer link and the importance of raising Fatty Liver awareness.

S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

S3-E51.3 – AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation explores patient advocate coverage of challenges facing liver health equity.

S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

S3-E51.2 – Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation focuses on fibrosis progression rates for diabetic vs. non-diabetic patients.

S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

S3-E51.1 – Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest.

S3-E51 - A Preview of the 2022 AASLD Liver Meeting

S3-E51 – A Preview of the 2022 AASLD Liver Meeting

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of key presentations and posters of interest.

S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage

S3-E50.5 – FIB-4 as a Front-Line Tool for Primary Care Triage

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver disease. This conversation explores the use of FIB-4 as a front-line tool for primary care. The advocates share their final thoughts on a change they can make in their country in the next 12 months that might extend beyond the country’s borders.

S3-E50.4 - Economics and Challenges of Pathway Design

S3-E50.4 – Economics and Challenges of Pathway Design

The panelists investigate the economics of pathway design within a wider discussion on the role of patient empowerment in putting a dent in Fatty Liver disease. This conversation observes challenges and opportunities for effective solutions.

S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines

S3-E50.3 – Patient Input for Clinical Care Pathways and Guidelines

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation highlights patient advocate contributions toward developing clinical care pathways and guidelines.

S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools

S3-E50.2 – The Future of Digital Therapeutics and Patient Wellness Tools

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores the prospect of digital therapeutics as a Pharma-supported patient wellness tool.

S3-E50.1 - Patient Needs and Inputs for Trial Design

S3-E50.1 – Patient Needs and Inputs for Trial Design

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores patient needs and inputs for trial design and the extent to which they are considered.

S3-E50 – Focus on Patient Advocacy

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. The group explores topics ranging from the economics of drug development to the future of digital therapeutics, all centering around the patient perspective.

S3-E49.4 - Delivering Meaningful Liver Test Results to Patients

S3-E49.4 – Delivering Meaningful Liver Test Results to Patients

Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to discuss the recent NICE meeting on use of VCTE in primary care settings. In this conversation, the group explores how to create and train on delivering meaningful test results to patients.

S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status

S3-E49.3 – Linking Liver Outcomes and Socioeconomic Status

Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to investigate the link between socioeconomic status and liver health outcomes. In this episode, the group discusses the challenges of developing accessible pathways and who will administer FibroScan in a community setting.

S3-E49.1 - NICE on FibroScan for Primary Care

S3-E49.1 – NICE on FibroScan for Primary Care

Roger Green and Louise Campbell are joined by Professor Ian Rowe and Dr Kathryn Jack to discuss the recent NICE meeting on use of VCTE in primary care settings. The group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice in community settings.

S3-E49 NICE and VCTE Use in Community Settings

S3-E49 NICE and VCTE Use in Community Settings

Roger Green and Louise Campbell are joined by Professors Ian Rowe and William Alazawi and Dr Kathryn Jack to discuss the recent NICE meeting on use of FibroScan in primary care settings. As part of the discussion, the group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice.

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

S3-E48.5 – Phase 3 Results of the REVERSE Trial by Intercept

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation the group discusses Phase 3 results of the REVERSE trial by Intercept.

S3-E48.3 - More Positive Phase 2B Results from Poxel

S3-E48.3 – More Positive Phase 2B Results from Poxel

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the group explores more positive Phase 2B results from Poxel’s DESTINY-1 Trial.

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

S3-E48.2 – Phase 2B ‘Wow!’ Results from Akero’s HARMONY Trial

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss eye-opening Phase 2B results from Akero’s HARMONY Trial.

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

S3-E48.1 – Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss the positive results of Altimmune’s 12 week Phase 1B study of pemvidutide.

Review of Exciting Clinical Trial Press Releases

S3-E48 – Review of Exciting Clinical Trial Press Releases

Stephen Harrison and Mazen Noureddin join regulars Jörn Schattenberg, Louise Campbell and Roger Green to review five recent press releases reporting on trial results from Altimmune, Akero, Poxel, Axcella and Intercept. Dubbed a Wow! episode, the panelists explore some of the most exciting and promising data of the last decade in NASH drug development.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud

Experience Nudge Learning! Interested in a new way of learning?